Ankit Agrawal, Msc, Mba Email & Phone Number

Naperville, Il, Us

I support the Chief Revenue Officer and leadership team by driving strategic initiatives and ensuring efficient daily operations within pricing and revenue enablement. My role involves optimizing sales and distribution channels, developing sophisticated customer retention methodologies, and leveraging data to inform company and sales strategies. I lead and motivate teams to achieve growth targets, negotiate high-level contracts, and implement cutting-edge sales and revenue tech stacks to streamline processes and enhance decision-making. My goal is to maximize productivity, improve performance, and drive profitable growth through well-rounded business insights and innovative solutions.

Focused on helping my clients (CxOs) achieve their objectives by identifying value creation strategies and bridging the gap to create reliable execution. This requires recognition of the right operational and financial engineering strategies to deliver on my client’s core principles. My aim is to help clients unlock their full potential and realize their goals with greater certainty and reliability.Clients include portfolio companies of Ampersand Capital Partners, SK Capital Partners, Nighthawk Bio

Principals:Co-Producer, OthelloCo-Producer, SMASH on BroadwayCo-Producer, Sunset BLVDTouring Shows:Producer, Pretty Woman on Tour Co-Producer, Life of Pie on TourCo-Producer, Dear Evan Hansen on TourOther Shows:TOOTSIE The Comedy Musical on BroadwayCabaret at The Kit Kat Club

Les Ulis, Fr

Écully, Auvergne-Rhône-Alpes, Fr

SEQENS is a worldwide leader in the development and production of active ingredients, pharmaceutical intermediates, specialty ingredients and cosmetics & personal care leveraging 24 manufacturing sites, 10 R&D centers and 3,400 employees in 10 countries. As an integrated player across the value chain, from raw materials to active ingredients and from research and development to industrialization, SEQENS offers a broad portfolio of active ingredients, pharmaceutical intermediates and specialty ingredients.

Albany, Ny, Us

•As a strategic advisor to the Chief Commercial Officer (CCO), I developed executive strategies that grew revenue from $650M to $1,150M in three years, while achieving a 25% CAGR and increasing EBITDA margins from 14% to 21%.•Successfully managed a team of 8 direct reports, with oversight for global commercial/market insights, forecasting & analytics, strategic/brand planning, go-to-market (GTM) strategy, product management, sales operations, variable compensation and operational excellence. •Conducted detailed financial analysis and valuation modeling to assess potential investment opportunities, resulting in successful investments in high-growth companies.

Albany, Ny, Us

•Revamped commercial organization and established a strategic thinking capability by balancing the team and incorporating sales and marketing strategies linked to scenario planning and data-driven decision-making.•Successfully managed the development of small molecule antivirals and medical countermeasure drugs for US military defense, earning international recognition as a BARDA CDMO network member. Secured a $200M contract with the US government and state of New Mexico to build an industrial BSL-2 sterile fill/finish facility in Albuquerque, expanding the company's capabilities and reputation.•Contributed to industry knowledge by publishing an article in the Drug Development & Delivery Journal (2021, Oct; 21(2)) on sterile drug product manufacturing during a global pandemic with Agrawal, A., Aungst, R., Hamer, J., and Solow, B.

Albany, Ny, Us

•As the leader of all profitability initiatives, I successfully implemented and oversaw contract management, price management, and commercial strategies to drive business growth.•Achieved outstanding results with 174% Y/Y target attainment and over 350 basis points of bottom-line EBITDA growth.•Led cross-functional teams to develop pricing models and analytical tools that provided real-time visibility into pricing performance and facilitated data-driven decision-making.•Mentored and trained team members on pricing strategy and analytics, resulting in increased productivity and improved pricing outcomes.

Tokyo, Jp

•As the leader of FP&A for all contracted commercial and government contracts, I was responsible for overseeing financial planning and analysis for TPUSA net sales of $5B.•Managed a contracts and pricing team of 35, including five direct reports, and provided strategic guidance and direction to ensure accurate financial reporting and forecasting.•Led detailed analysis and projections of all gross-to-net activity, including rebates and chargebacks totaling $2.7B annually, which represented the largest P&L for the pharmaceutical company.•Developed and implemented financial models to support business decision-making and strategic planning, including scenario planning and sensitivity analysis.

Tokyo, Jp

•As the director of a team of eight direct reports and a global team of 90, including several service firms, I oversaw the execution and integration of global zero-based budgeting (ZBB) to create best-in-class capabilities.•Exceeded annual cost reduction targets of $300M and successfully delivered 125% of the target, resulting in a significant improvement of +400 bps to core earnings margin between 2017 and 2018 for the organization.•Generated $600M in savings over two years across enterprise-wide G&A functions, including commercial, finance, HR, supply chain/ops, IT, and others, leading to a 400 bps core margin enhancement.•Led change management efforts to ensure successful adoption of ZBB across the organization and coached team members to ensure their professional growth and development.This role comprised three initiatives. (1) Pay less: Efforts to reduce purchasing costs. (2) Buy less: Cost-cutting efforts will expand company wide since 2017. (3) Work better: Reduce management costs.

Tokyo, Jp

•Developed and executed commercial strategy for a portfolio of 14 established and gout brands with a total P&L of $900M, achieving double-digit revenue growth and market share gains.•Led the development and implementation of brand plans, launch strategies, and lifecycle management for all established brands, resulting in a 12% increase in revenue and market share growth.•Chaired and facilitated monthly business planning meetings for all Established Brands (including Actos Family, Nesina, Rozerem, Prevacid Family, and AGx) and Gout (Uloric, Colcrys), aligning cross-functional stakeholders and driving agile decision-making and execution.•Developed and implemented innovative go-to-market strategies for 14 established and gout brands, leveraging customer insights, digital channels, and strategic partnerships to drive demand and maximize brand value.

New York, Ny, Us

*Booz & Company was acquired by PwC and formally rebranded it to Strategy&*Selected engagements listed belowGLOBAL SEPARATION STRATEGY & OPERATIONAL READINESSAdvised on the separation process (key decisions, cost estimates, timeline and roadmap) for a Top 3 PharmaCo that was exploring the possibility of separating the business into two separate companies: one which focused on higher margin innovative products and one which focused on established generic products. US HEMATOLOGY-ONCOLOGY FRANCHISE STRATEGY: Developed portfolio strategy for client’s hematological-oncology business unit including a prioritized strategy for a mix of early stage and late stage assets (including novel-novel combinations of internal assets)MARKET ENTRY STRATEGYBuilt low cost and alternative distribution strategies for a top 5 payor’s consumer business products with a go-to-market roadmap for six targeted high-potential markets with a forecasted annual revenue stream of $3.2Bn

New York, Ny, Us

CRO (CONTRACT RESEARCH ORGANIZATION) GROWTH STRATEGYDeveloped a comprehensive global inorganic turnaround strategy for a Top 3 CRO followed on by a rapid search and screen resulting in a defined company acquisition roadmap in-line with market needs totally USD $500MnSTRATEGIC COST TRANSFORMATION:Conducted an “outside-in” opportunity valuation for a $100Bn biopharmaceutical-company yielding identification of $1.7Bn in growth and savings enterprise-wide (commercial, R&D, Mfg. Supply Chain/Ops, IT, etc.) while re-focusing capability investments on competitiveness

Chicago, Us

As part of a joint venture between GE Healthcare and the University of Pittsburgh Medical Center, I collaborated on developing downstream market positioning strategies for FDA-regulated medical devices and software in the field of digital pathology. Our goal was to enhance utilization and adoption of these technologies. While the business has since been divested and closed, the experience provided valuable insights into the healthcare industry and the commercialization of innovative medical technologies.

Washington, D.C., Us

Omaha, Nebraska, Us

Omaha, Nebraska, Us

Conducted research across diverse areas including: pediatric solid organ transplantation and efficacy of perioperative echocardiography. I had several roles which included writing the IRB protocol, gathering data, entering the data into a database, conducting the biostatistical analysis, assist in manuscript preparation, and eventually become lead coordinator. Additionally, I learned several techniques including: performing a standard echocardiography (TTE/TEE), intubation with rapid sequence induction, central line placement, and the ability to communicate with patients effectively.*Logged over 2,000 operating room hours and 1,000+ patient care management hours.

Executive Mba, Business Administration And Management

Master Of Science (M.Sc.), Health Care Policy & Management

Bachelor Of Science - Bs, Biotechnology, Minor: Chemistry